GLP-1 receptor (Glucagon like peptide-1 receptor) is a receptor protein found in the neurons of the brain and the beta cells of pancreas. GLP-1 receptor is involved in regulating the process of insulin secretion in the body. GLP-1 and glucagon are the natural endogenous agonists of GLP-1 receptor. An agonist is a chemical entity which induces a biological response by binding to a receptor and activating it. Some of the other agonists of GLP-1 receptor include exenatide, lixisenatide, albiglutide, liraglutide, dulaglutide, and semaglutide. GLP-1 receptor agonists are commonly used for the treatment of diabetes and obesity. When an agonist binds to the GLP-1 receptor the receptor becomes activated and results in stimulation of adenylyl cyclase pathway. Adenylyl cyclase pathway leads to increased production and release of insulin in the beta cells of pancreas. GLP-1 receptors expressed in the brain neurons are responsible for controlling appetite. GLP-1 receptor is also expressed in stretch responsive sensory neurons of the stomach and intestines. These GLP-1 receptor neurons, when activated can cause changes in the breathing and heart rate. GLP-1 receptor agonists, also known as incretin mimetics, are advantageous over traditional insulin secretagogues, such as sulfonylureas or meglitinides as they pose a low risk of causing hypoglycemia or low blood sugar.
Market Dynamics
The increasing incidence of diabetes and obesity, rising research and development activities for the development of novel therapeutics for the treatment of diabetes and obesity, and increasing adoption of inorganic growth strategies such as merger, acquisitions, distributive agreements, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global GLP-1 receptor agonist market over the forecast period.
For instance, according to the Pan American Journal of Public Health, the number of people living with type 1 diabetes in the Americas is expected to increase from 35 million in 2000 to 64 million in 2025, out of which Latin America and Caribbean region would account for 62% or 40 million people in 2025.
Key features of the study:
- This report provides in-depth analysis of the global GLP-1 receptor agonist market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global GLP-1 receptor agonist market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Eli Lilly and Company, GlaxoSmithKline plc, Novo Nordisk A/S, PegBio Co., Ltd., AstraZeneca, Intarcia Therapeutics, Inc., Amylin Pharmaceuticals, Inc., Sanofi, Hanmi Pharm. Co., Ltd., Pfizer Inc., Amgen Inc., Innovent Biologics, Jiangsu Hengrui Medicine Co., Sun Pharmaceuticals Industries Ltd., and 9 Meters Biopharma, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global GLP-1 receptor agonist market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global GLP-1 receptor agonist market
Detailed Segmentation:
- Global GLP-1 Receptor Agonist Market, By Drug Class:
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- Global GLP-1 Receptor Agonist Market, By Route of Administration:
- Global GLP-1 Receptor Agonist Market, By Application:
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- Global GLP-1 Receptor Agonist Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global GLP-1 Receptor Agonist Market, By Region:
- North America
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Class
- Exenatide
- Liraglutide
- Dulaglutide
- Lixisenatide
- Albiglutide
- Semaglutide
- By Route of Administration
- By Application
- Type 2 Diabetes Mellitus
- Obesity
- Liver Cirrhosis
- Non-alcoholic Steatohepatitis
- Others (Others include Cardiovascular Disease and Type-1 Diabetes)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Eli Lilly and Company*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- GlaxoSmithKline plc
- Novo Nordisk A/S
- PegBio Co., Ltd.
- AstraZeneca
- Intarcia Therapeutics, Inc.
- Amylin Pharmaceuticals, Inc.
- Sanofi
- Hanmi Pharm. Co., Ltd.
- Pfizer Inc.
- Amgen Inc.
- Innovent Biologics
- Jiangsu Hengrui Medicine Co.
- Sun Pharmaceuticals Industries Ltd.
- 9 Meters Biopharma, Inc.
“*” marked represents similar segmentation in other categories in the respective section.
